Psy105 - Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Belgian Perspective
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2680
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV